期刊文献+

干扰素栓配合派特灵治疗宫颈上皮内瘤变Ⅰ、Ⅱ级临床疗效观察 被引量:2

Clinical observation of interferon combined with Patling treatment of cervical intraepithelial neoplasia grade Ⅰ、Ⅱ
下载PDF
导出
摘要 目的:探讨干扰素栓配合派特灵治疗宫颈上皮内瘤变(CIN)Ⅰ、Ⅱ级的疗效。方法:收治病理学诊断为CINⅠ级和CINⅡ级患者120人,随机分为两组,观察组60例,其中人乳头瘤病毒HPV高危亚型感染55例,给于干扰素栓加派特灵进行治疗;对照组60例,其中HPV高危亚型感染52例,患者仅进行观察不做治疗。两组于观察组用药结束3个月后均进行TCT和HPV复查。结果:应用干扰素栓加派特灵治疗3个疗程后,治疗组52例(86.7%)CIN转阴;对照组19例(31.7%)CIN转阴。两组治疗CIN的有效性相比差异有统计学意义(P<0.01)。应用干扰素栓加派特灵治疗后,观察组49例(81.7%)HPV高危亚型转为阴性,对照组19例(31.7%)HPV高危亚型转阴,两组相比差异具有统计学意义(P<0.01)。结论:应用干扰素栓加派特灵治疗CINⅠ级和CINⅡ级是安全有效的,为临床处理提供了新思路。 Objective:To investigate the effect interferon combined with Patling treatment of cervical intraepithelial neoplasia gradeⅠ、Ⅱ.Methods:From November 2010 to December 2012,120 patients admitted pathological diagnosis of CINⅠ and CINⅡ grade,were randomly divided into two groups:observation group,60 cases,including 55 cases with high-risk HPV subtypes of human papillomavirus infection,treat with interferon combined Patling;control group of 60 patients,including 52 cases with high-risk subtypes of HPV infection,patients were only observed but no treatment.three months later at end of the observation group treatment,two groups of patients were carried TCT medication and HPV review.Results:After application of interferon deployed Trane 3 courses of treatment,the treatment group 52 cases(86.7%)CIN negative;the control group 19 cases(31.7%)CIN negative.CIN effectiveness was statistically significant(P<0.01)in two compared group.In observation group 49 cases(81.7%)HPV high-risk subtypes became negative,in control group 19 cases(31.7%)HPV high-risk subtypes negative,the difference was statistically significante in two groups(P<0.01).Conclusion:interferon combined with Patling treatment grade CINⅠ and CINⅡ level is safe and effective,and providing new ideas for clinical treatment.
作者 尚维群 李坤
出处 《中国社区医师(医学专业)》 2014年第5期94-95,共2页
关键词 干扰素栓 派特灵 宫颈上皮内瘤变 Interferon PatLing Cervical intraepithelial neoplasia
  • 相关文献

参考文献4

二级参考文献24

  • 1李校坤,姚崇瞬,黄亚东,肖健.现代技术在莪术研究中的应用[J].药物生物技术,2005,12(2):134-137. 被引量:16
  • 2李隆玉,乔志强.宫颈癌前病变患者治疗前后HPV病毒负荷量变化的临床分析[J].中华肿瘤防治杂志,2006,13(4):298-300. 被引量:24
  • 3薛书霞,王淑安,王晓慧,杨立杰,王晓敏,王玲玲.α-干扰素不同治疗方式对HPV隐性感染患者的临床随机实验研究[J].中国妇幼保健,2007,22(10):1406-1407. 被引量:6
  • 4[2]Munoz N,Bosch FX,Sanjose S,et al.Epidemiologic classification of humanpapillomavirus types associated with cervical cancer.N Engl J Med,2003,348:518-527. 被引量:1
  • 5[3]Einstein MH,Goldberg GL.Human papillomavirus and cervical neoplasia.Cancer Invest,2002,20:1080-1085. 被引量:1
  • 6[4]Bosch FX,Munoz N.The viral etiology of cervical cancer.Virus Res,2002,89:183-190. 被引量:1
  • 7[5]Ronco LV,Karpova AY,Vidal M,et al.Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity.Genes Dev,1998,12:2061-2072. 被引量:1
  • 8[6]Nees M,Geoghegan JM,Munson P,et al.Human papillomavirus type 16 and E7 proteins inhibit differentiation - dependent expression of tansforming growth factor - beta 2 in cervical keratinocytes.Cancer Res,2000,60:4289-4298. 被引量:1
  • 9[7]Lippman SM,Kavanagh JJ,Paredes-Espinoza M,et al.13-cis-retinoic acid plus interferon-α-2a:Highly active systemic therapy for squamous cell carcinoma of the cervix.J Natl Cancer Inst,1992,84:241-245. 被引量:1
  • 10[8]Stellato G.Intralesional recombinant alpha 2B interferon in the treatment of human papillomavirus-associated cervical intraepithelial neoplasia.Sex.Trans.Dis,1992,19:124-126. 被引量:1

共引文献38

同被引文献29

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部